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The cancer drug, Imatinib, is a selective Abl kinase
inhibitor that does not inhibit the closely related ki-
nase c-Src. This one drug and its ability to selectively
inhibit Abl over c-Src has been a guiding principle in
virtually all kinase drug discovery efforts in the last
15 years. A prominent hypothesis explaining the se-
lectivity of Imatinib is that Abl has an intrinsic ability
to adopt an inactive conformation (termed DFG-
out), whereas c-Src appears to pay a high intrinsic
energetic penalty for adopting this conformation,
effectively excluding Imatinib from its ATP pocket.
This explanation of the difference in binding affinity
of Imatinib for Abl versus c-Src makes the striking
prediction that it would not be possible to design
an inhibitor that binds to the DFG-out conformation
of c-Src with high affinity. We report the discovery
of a series of such inhibitors. We use structure-activ-
ity relationships and X-ray crystallography to confirm
our findings. These studies suggest that small
molecules are capable of inducing the generally
unfavorable DFG-out conformation in c-Src. Struc-
tural comparison between c-Src in complex with
these inhibitors allows us to speculate on the differ-
ential selectivity of Imatinib for c-Src and Abl.
INTRODUCTION
Protein kinases represent one of the largest superfamilies of drug
targets across all therapeutic areas. The central challenge in the
development of kinase-inhibitor drug candidates is in targeting
the disregulated kinase while avoiding inhibition of non-dis-
ease-related kinases containing closely related ATP binding
pockets. Imatinib, the first clinically approved kinase inhibitor,
provides a remarkable example of a highly selective inhibitor of
the translocation product Bcr-Abl (Capdeville et al., 2002; Saw-
yers, 2002). Imatinib potently inhibits Bcr-Abl, the oncogene that
drives chronic myelogenous leukemia, but does not inhibit the
cytoplasmic tyrosine kinase c-Src, despite the fact that the two
kinases share almost completely identical amino acids lining
the ATP binding pocket that Imatinib contacts (Figure 1A; Schin-
dler et al., 2000; Seeliger et al., 2007). Significant medicinal
chemistry, structural biology, and computational modeling
efforts have focused on understanding the differential selectivity
of Imatinib for Bcr-Abl and c-Src.Chemistry & Biology 15, 1015–The first insight into the basis for selectivity of Imatinib was
revealed when Kuriyan and coworkers solved the Imatinib-Abl
cocrystal structure (Nagar et al., 2002; Schindler et al., 2000).
This structure revealed a previously unobserved kinase confor-
mation indicating that Imatinib binds Abl in a catalytically inactive
conformation defined by a crank shaft-like displacement of the
N-terminal region of the activation loop of the kinase effecting
a dramatic change in the conformation of the Asp-Phe-Gly
(DFG) triad. This conformational change has been subsequently
observed in other protein kinase drug cocrystal structures (Irk,
Kit, Flt3, p38 Mapk and B-Raf; Griffith et al., 2004; Hubbard
et al., 1994; Mol et al., 2004; Pargellis et al., 2002; Wan et al.,
2004) and has been termed the type II or DFG-out conformation
(ATP competitive inhibitors that bind to kinases in the active
conformation are termed type I or DFG-in binders; Figures 1B
and 1C; Liu and Gray, 2006). The identification of an inactive
conformation of Abl bound by the highly selective inhibitor
Imatinib has guided many successful medicinal chemistry cam-
paigns in search of selective kinase inhibitors (Angell et al., 2008;
Cumming et al., 2004; Gill et al., 2005; Heron et al., 2006; Okram
et al., 2006).
A wealth of data currently supports the view that the Imatinib-
bound conformation (DFG-out) of Abl is thermodynamically
stable in complex with Imatinib, but that such conformations
require energetically unfavorable interactions in c-Src com-
plexes (Levinson et al., 2006; Nagar et al., 2002; Seeliger et al.,
2007; Vajpai et al., 2008). Imatinib has been crystallized in both
its potent target, Abl (Nagar et al., 2002; Schindler et al., 2000),
as well as its poorly inhibited target, c-Src (Seeliger et al.,
2007). Surprisingly, the Imatinib/cocrystal structures are virtually
identical despite the significantly different affinities of Imatinib for
the two protein kinases. Efforts to construct mutant forms of
c-Src with the ability to be potently inhibited by Imatinib were
only partially successful, which led Kuriyan and coworkers to
suggest a distributed thermodynamic penalty for c-Src to adopt
the DFG-out conformation (Seeliger et al., 2007). The importance
of kinase conformational preference over precise amino acid
identity is highlighted by studies with the Imatinib target receptor
kinase, c-Kit. Although c-Kit is more closely related to c-Src than
Abl in the amino acids lining the ATP binding pocket, c-Kit is
more potently inhibited by Imatinib (Deininger et al., 2005). Struc-
tural studies of c-Kit in the absence of ligand (ATP or Imatinib)
show the kinase adopts the DFG-out conformation, suggesting
the Imatinib-bound conformation is stable and preformed in
the absence of Imatinib, thereby explaining its Imatinib sensitivity
(Mol et al., 2004).
The resulting widely held explanation of the discrepancy
in affinity of Imatinib despite the close similarity in structure of1022, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1015
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Type II Inhibition of c-SrcFigure 1. Features of Imatinib binding to Src and Abl
(A) Schematic representation of Imatinib contacts identified in its complexes with c-Src (PDB ID 2OIQ) and Abl (PDB ID 1IEP). The upper and lower sequences are
aligned based on structural superposition and the numbering scheme in based on c-Src. Residues are grouped based on their location within the N-lobe, hinge
region, and C-lobe of the kinase domain. The interaction between Imatinib and Tyr253 in Abl (Phe278 in c-Src) was not observed in the c-Src complex and is
depicted by a yellow star.
(B) Type I inhibitors, such as PP1, occupy the adenosine pocket forming multiple hydrogen bonds with the hinge region of the kinase and threonine gatekeeper.
Themolecular envelop of PP1 (depicted by the blue shadow) is not thought to influence the conformation of the DFGmotif (shown here in the ‘‘in’’ conformation) or
helix aC (shown in the ‘‘out’’ conformation).
(C) Type II inhibitors, such as Imatinib, engage the hinge binding region and extend into the pocket created by the DFG flip. The extended portion of Imatinib
(depicted by the pink shadow) directly senses the ‘‘out’’ conformation of the DFGmotif. Common features of type II binding are the interaction with the conserved
glutamate within helix aC and the backbone amide of the DFG triad (Liu and Gray, 2006).the two drug-protein complexes is based on the relative propen-
sity of the two kinases to adopt the relevant drug-bound
(DFG-out/type II) conformation: Abl is predicted to prefer the
DFG-out conformation relative to c-Src, and because Imatinib
binds to the type II conformation of the kinase, its affinity is higher
to Abl than to c-Src. This explanation of the difference in binding
affinity of Imatinib for Abl versus c-Src makes the striking predic-1016 Chemistry & Biology 15, 1015–1022, October 20, 2008 ª2008tion that it would not be possible to design an inhibitor, that binds
potently to the type II conformation of c-Src.
RESULTS
Weasked ifwecould develop aDFG-out binder for c-Src as a test
of this prediction. We applied an approach pioneered by Liu,Elsevier Ltd All rights reserved
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Type II Inhibition of c-SrcGray, and coworkers whereby type II (DFG-out) kinase inhibitors
can be created by fusing a so-called hinge binding element of
a type I kinase inhibitor to an element capable of binding in the
pocket created by the characteristic DFGmovement in type II in-
hibitor-bound structures (Liu andGray, 2006;Okram et al., 2006).
We chose the hinge-binding element from thewell-characterized
pyrazolopyrimidine PP1. We chose PP1 because it has been ex-
amined at both the structural and functional level and was first
identified as a selective c-Src family tyrosine kinase inhibitor
(Hanke et al., 1996; Liu et al., 1999; Schindler et al., 1999).
In order to select the DFG-out binding element for our design,
weexamined the cocrystal structuresof Abl, Raf, andp38 in com-
plex with Imatinib, BAY43-9006, and BIRB796, respectively;
three chemically distinct type II inhibitors with three different
kinase targets (Pargellis et al., 2002; Schindler et al., 2000; Wan
et al., 2004). Each inhibitor follows nearly the identical path within
the active site pockets, despite their chemical uniqueness (see
Figure S1 available online). A key feature of the observed binding
modes is the interaction with a portion of the activation segment
termed the DFG motif and a highly conserved glutamic acid
residue within helix aC, which are mediated through the amide/
urea linker and hydrophobic portions of the inhibitors. Movement
of the Asp residue out and the Phe residue in (hence ‘‘DFG-out’’)
by a flip of approximately 180 degrees relative to their position in
the active state creates the cavity that is filled by these inhibitors.
The extended portions of each inhibitor are remarkably similar,
and their interactions with the kinase aremediated through highly
conserved residues within the ATP pocket, suggesting that the
general inhibitor features could be applied to other kinases.
We hypothesized that derivatization on the phenyl ring in PP1
with am-trifluoromethyl phenylurea groupwould create an inhib-
itor that could engage the DFG-out pocket. The pyrazolopyrimi-
dine core of PP1 occupies the portion of the active site within
which the adenosine ring of ATP normally sits, forming key hydro-
gen bonds with the backbone of the kinase hinge region (Fig-
ure 1B). Because this portion of the active site is not subject to
allosteric control, PP1 and type I inhibitors should bind to their
kinase targets irrespective of their activation state. We synthe-
sized a panel ofmoleculeswith this design searching for an inhib-
itorwith tight (nM) binding affinity for c-Src.Becauseof the known
sensitivity of PP1 derivatives to sterically bulky phenyl replace-
ments, we reasoned that if we identified a potent binder it would
be likely to adopt a type II orientation in order to accommodate
the bulky phenyl substituent.
Our modeling suggested that addition of a methylene group
between the pyrazolopyrimidine core and the phenyl ring would
provide flexibility in guiding the m-trifluoromethyl phenyl urea
substitution into the DFG pocket. We therefore synthesized
compounds 1-4, in which the phenyl group of PP1 has been
replaced with a benzyl functionality and the N1 position of the
pyrazole ring has been variedwith different alkyl groups (Figure 2,
middle). In our design strategy, we also anticipated that a direct
link between the pyrazolopyrimidine core and the derivatized
phenyl could avoid a potential negative interaction with the thre-
onine gatekeeper, and thus we created compound 5 (Figure 2,
bottom). Each molecule was prepared based on previously
established routes for generating pyrazolopyrimidines (Bishop
et al., 1998, 1999; Blethrow et al., 2004) with the exception that
the urea linker was appended through inclusion of a nitro groupChemistry & Biology 15, 1015–1in the starting material, which in the final synthetic steps was
reduced and coupled to m-trifluoromethyl phenyl isocyanate to
generate the type II analogs.
To ascertain the potency of our designed compounds, we ex-
amined their ability to inhibit kinase domain fragments of c-Src
and Abl that were expressed and purified identically from bacte-
ria in their unphosphorylated forms. We measured half maximal
inhibitory concentrations (IC50) using an in vitro assay in which
the kinase catalyzes phosphorylation of a synthetic peptide sub-
strate in the presence of 100 mM ATP and varying amounts of
inhibitor (Figure 2). From this analysis, we determined IC50 values
for Imatinib of 24,370 and 11 nM for c-Src and Abl, respectively.
These values are in close agreement to published values and
highlight the inherent selectivity of Imatinib for Abl with respect
to c-Src (Seeliger et al., 2007).
Compound 1was found to inhibit c-Src with an IC50 of approx-
imately 6.2 mM, whereas a control compound in which the urea
linker was placed at the para position of the benzyl ring lacked
any detectable inhibitory activity (data not shown). In measuring
the IC50 values for 1-4, we observed an interesting correlation
between the size of the alkyl group substitutions and selectivity
for c-Src and Abl (Figure 2). The methyl derivative 1 was the
weakest inhibitor against both c-Src and Abl, followed by the
isopropyl 2 and t-butyl 3 compounds, which gained moderate
potency, with the optimal derivative appearing to be the cyclo-
pentyl substitution 4, with an IC50 of 480 nM for c-Src (Figure 2).
Curiously, although most compounds in this set equally inhibited
both c-Src and Abl, the cyclopentyl derivative showed a repro-
ducible selectivity toward c-Src over Abl of approximately
5-fold. Although small, thismodest degree of selectivity appeared
significant in comparison to the yet smaller IC50 value differ-
ences between c-Src and Abl for compounds 1, 2, and 4. Com-
pound 5 was the most potent inhibitor that we identified, with
IC50 values of 25 and 41 nM for c-Src and Abl, respectively (Fig-
ure 2). Interestingly, the potency of 5 approaches that of Imatinib
for Abl, but without any significant discrimination against c-Src.
In our small test of compounds we identified two interesting
features: compound 3 with unexpected selectivity for c-Src,
and compound 5 with extremely high potency for both c-Src
and Abl. These intriguing features made us wonder if we had
achieved our designedmode of binding, and to resolve this issue
we determined cocrystal structures of c-Src bound to inhibitors
3 and 5.
Binding Mode Revealed by Cocrystallography
Purified c-Src kinase domain in complex with 3 and 5 yielded
crystals that diffracted to 2.8 and 2.3 A˚, respectively. Both struc-
tures were determined by molecular replacement, finding a
single copy of c-Src within the asymmetric unit of the P21 crystal
form for the c-Src-3 complex and two copies of c-Src in the P1
crystal form of the c-Src-5 complex. Interestingly, only one
kinase molecule within the c-Src-5 complex appeared to contain
inhibitor. This feature was observed previously in the cocrystal
structure of c-Src with Imatinib, where only one kinase within
the asymmetric unit was found to be in a drug complex despite
molar equivalents of the protein and inhibitor at a concentration
well above their binding constant (Seeliger et al., 2007). The
structures of c-Src in complex with 3 and 5 are shown in Figure 3,
with corresponding magnification of the active site.022, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1017
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Type II Inhibition of c-SrcFigure 2. IC50 values of Imatinib, and compounds 1-5 for both c-Src and Abl
The values adjacent to the bar graph represent the mean calculation and uncertainty in mM units.As shown, the pyrazolopyrimidine core for both inhibitors lies
deep within the adenosine pocket that is lined by the hinge
region of the kinase. In comparison to PP1, the plane of the pyr-
azolopyrimidine rings of both 3 and 5 deviate slightly with respect
to each other. As a result of the altered geometry, both 3 and 5
only form a single hydrogen bond to the main chain carbonyl
of Glu339. Compound 3 is shifted away from the side-chain hy-
droxyl of the Thr338 gatekeeper, and as a result does not form
the hydrogen bond seen in PP1 or in 5 with this residue. As an-
ticipated, both the benzyl group of 3 and the phenyl group in 5
lie juxtaposed to the gatekeeper; both which are twisted out of
plane relative to the pyrazolopyrimidine ring. In both 3 and 5,
the urea extension forms the designed hydrogen bond with the
side chain of Glu310 within helix aC, whereas the m-trifluoro-
methyl phenyl portion of both compounds lie within a pocket
lined by residues Leu317, Leu322, Val402, Met314, and His384.
As a result of occupying this space, Asp404 and Phe405 are flip-
ped near 180 degrees relative to their active-state positions. In
the c-Src–5 complex, the side-chain carbonyl of Asp404 forms1018 Chemistry & Biology 15, 1015–1022, October 20, 2008 ª2008a hydrogen bond to the main-chain amide of Gly406 (Figure 3B).
To our knowledge, this precise configuration has not been
observed in crystal structures of DFG-out kinases, but has
been hypothesized to occur during the DFG flip as revealed in
molecular dynamic simulations (Levinson et al., 2006). Interest-
ingly, the configuration of the aspartic acid side chain through to
the glycine amide is strikingly similar to the structure of a beta
bend (Fersht, 1999). In a classic beta bend, a nine-atom turn
along the main chain separates a carbonyl acceptor from an
amide donor, and often contains a CH2- glycine between the
donor-acceptor pairs. Here the side chain of Asp404 appears to
supply both the carbonyl acceptor and interveningCH2- group.
In both structures of c-Src described here, the configuration of
the DFG triad and the position of Glu310 of helix aC adopt con-
formations that deviate from what was previously observed in
either apo c-Src or the PP1-bound form of the closely related
enzyme HCK (Schindler et al., 1999; Xu et al., 1997). Rather, 3
and 5 recognize the DFG-out configuration of c-Src that is
similarly engaged by Imatinib.Elsevier Ltd All rights reserved
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Type II Inhibition of c-SrcFigure 3. Crystal structures of compounds 3 and 5 bound to c-Src
(A) Cartoon representation of c-Src in complex with 3. The side chains of Thr338, Glu310, main-chain atoms within the hinge region, and both main-chain and
side-chain atoms of the DFG triad are shown as sticks. Hydrogen bonding interactions are shown as dashed lines. Panels B to D are similarly labeled.
(B) Magnification of the active site of c-Src in complex with 3.
(C) Cartoon representation of c-Src in complex with 5.
(D) Magnification of the active site of c-Src in complex with 5.Chemistry & Biology 15, 1015–1022, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1019
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Type II Inhibition of c-SrcFigure 4. Structural differences in the binding of 3, 5, and Imatinib to c-Src
(A) Stereo figure of a structural superposition of 3 in complex with c-Src (yellow) and Imatinib in complex with Abl (purple; PDB 1IEP) or c-Src (orange; PDB 2OIQ).
The red arrow highlights deviations in the path of the respective P loops. Tyr253 in Abl and the cyclopentyl (Cp) group of 3 fill a space that is unoccupied within the
c-Src–Imatinib complex.
(B) Stereo figure of 3, 5, and Imatinib in complex with c-Src. The gatekeeper is highlighted as a semitransparent surface. The relative position of the inhibitors
could make them differentially sensitive to gatekeeper mutations, such as the clinically relevant Thr315Ile mutation found in Abl.DISCUSSION
In their hybrid design approach, the set of type II inhibitors that
were successfully developed for Abl by Liu, Gray, and coworkers
started from four different type I scaffolds (Okramet al., 2006). It is
noteworthy to mention that each of the designed inhibitors was
tested against a panel of protein kinases including c-Src. Interest-
ingly, each type II variant exhibited decreased affinity for c-Src
relative to the starting scaffolds, whereas they gained potency
and selectivity for Abl. Although these experiments suggested
that a hybrid design approach is feasible, they also hinted at the
restricted effectiveness of new type II inhibitors toward certain ki-1020 Chemistry & Biology 15, 1015–1022, October 20, 2008 ª2008nases. The discovery of compounds 3 and 5 open up the very real
possibility of further developing potent DFG-out binders for c-Src
as an effective inhibitor design strategy. In many cases inhibitors
that share the general features of DFG-out binders may already
exist (for example, Dimauro et al., 2006), but have been ruled
out as type II inhibitors of c-Src because it would have seemed
highly unlikely based on the precedence that has been set by
Imatinib. Further exploration of c-Src in complex with DFG-out
binders will provide a greater understanding of the molecular
recognition principles of remarkable drugs such as Imatinib,
and might provide a basis for predictive modeling of kinase con-
formational dynamics and the relationship to inhibitor potency.Elsevier Ltd All rights reserved
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Type II Inhibition of c-SrcAssuming that each inhibitor must overcome the same ener-
getic barrier needed to induce the DFG-out conformation, we
can begin to speculate on the increased affinity of 3 and 5 versus
Imatinib for c-Src, keeping in mind that any region alone of the
inhibitors or protein likely contribute a fraction of the distributive
function that forms the basis for the bimolecular interaction. One
of themore significant differences between the c-Src complexes
and the Abl-Imatinib structure is in the path of the P loop
(Figure 4A); the region defined by the GXGXXG motif of kinases
within the b1-b2 linker and that forms the top shelf of the ATP
pocket. Notably, in the Abl-Imatinib complex, the P loop tightly
encloses the drug binding site in large part through residue
Tyr253, which folds back onto the lip of the pyrimidine core. In
the c-Src–Imatinib complex, the region occupied by Tyr253 of
Abl is left unoccupied, whereas in the c-Src–3 complex, the cy-
clopentyl group of the inhibitor itself fills this space. Experimen-
tally, it would be ideal to test if one could increase the potency of
Imatinib for c-Src by derivatizing its pyridine ring with a group
similar to the cyclopentyl of 3 to determine if this missing interac-
tion is partially responsible for the weak binding of Imatinib to
c-Src. Unfortunately it would be nearly impossible to maintain
the coplanar nature of the phenyl-pyrimidine rings in Imatinib
with such an analog due to intramolecular steric interactions
that would twist the rings out of planarity. Because the overall
binding conformation of compounds 1-4 are less sensitive to
the influence of substitutions at the R-1 position on the pyrazole
ring, this series of inhibitors could be a reliable measure of en-
gaging the Tyr253 pocket through varying steric bulk of the inhib-
itor. Indeed, the structure and activity of compounds 1-4 could
be explained based on the potential role of the Tyr253 region
as an affinity pocket, because there is a distinct structure activity
relationship when this substituent is varied.
Interestingly, one other distinguishing feature between the 3-, 5-
, and Imatinib complexes with c-Src is in the approach of these
inhibitors toward the gatekeeper pocket (Figure 4B). Notably,
the benzyl group of 3 and the phenyl ring of 5 are rotated away
from Thr338 relative to o-methyl-phenylamino portion of Imatinib
in a rank order that reflects the relative affinity of the drugs for
c-Src. This extra distance from the gatekeeper Thr suggests that
compounds1-5might bind tomutant kinases suchas the clinically
relevant Imatinib resistant Abl Thr315Ile kinase (Shah et al., 2002).
What have we learned from the discovery of potent DFG-out
binders to c-Src? We can conclude that the relative energy dif-
ferences between favored and disfavored conformational states
of particular kinases can be overcome by small molecules. This
finding implies that DGF-out binders and other such conforma-
tion-specific binders will not necessarily be kinase specific. Sup-
port for this view comes from recent studies on the development
of DFG-out binders of the p38 MAP kinase where it was found
that a series of biphenyl amides containing DFG-out kinase in-
hibitors are in fact less selective than traditional DFG-in binders
based on the same scaffold (Angell et al., 2008). Thus, conforma-
tion-specific kinase inhibitors are not de facto more selective
based on intrinsic kinase conformational preferences.
SIGNIFICANCE
Our results highlight a potential new utility of small molecule
ligands for protein kinases. Small molecules might be capa-Chemistry & Biology 15, 1015–1ble of inducing changes to secondary, tertiary, and even
quaternary structure of protein kinases and protein kinase
complexes in cells, which are not sampled by the protein
normally. This could open up the possibility of regulating
protein kinase function through inducing conformational
changes in protein-protein or enzymatic domains outside
of the kinase catalytic domain (Papa et al., 2003), providing
new therapeutic modalities.
EXPERIMENTAL PROCEDURES
Methods
A detailed description of methods used for protein expression and purification,
in vitro kinase assays, crystallization and structure determination, and chem-
ical synthesis are described in the Supplemental Data.
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3EL7 (Src-3 complex) and 3EL8 (Src-5 complex).
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Procedures, and Supplemental References and can be found with this article
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